Drug Search Results
More Filters [+]

Besilesomab

Alternative Names: besilesomab
Latest Update: 2023-08-17
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: IgG Imaging Agent,IgG Radioactive Agent

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: Orphan Drug - Bone Marrow Transplantation *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Colombia | Croatia | Denmark | Estonia | France | Germany | Hungary | Italy | Netherlands | Norway | Spain | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Great Ormond Street Hospital for Children NHS Foundation Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Besilesomab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Diabetic Foot|Skin Ulcer|Osteomyelitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-000514-21

P3

Completed

Osteomyelitis|Diabetic Foot|Skin Ulcer

2008-01-05

Recent News Events